Cargando…

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines

Oxaliplatin (OHP) treatment of colorectal cancer (CRC) frequently leads to resistance. OHP resistance was induced in CRC cell lines LoVo-92 and LoVo-Li and a platinum-sensitive ovarian cancer cell line, A2780, and related to cellular platinum accumulation, platinum-DNA adducts, transporter expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noordhuis, Paul, Laan, Adrianus C., van de Born, Kasper, Honeywell, Richard J., Peters, Godefridus J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696456/ https://www.ncbi.nlm.nih.gov/pubmed/31344863 http://dx.doi.org/10.3390/ijms20153619

Ejemplares similares

Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
por: Braun, M S, et al.
Publicado: (2003)

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine
por: Bijnsdorp, Irene V., et al.
Publicado: (2009)

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins
por: Virag, Piroska, et al.
Publicado: (2013)

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
por: Arango, D, et al.
Publicado: (2004)

Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2004)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2016)

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro
por: Bijnsdorp, I.V., et al.
Publicado: (2021)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-AS(r)OXALI(4000), a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS
por: Saintas, Emily, et al.
Publicado: (2017)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014)

Role of oxaliplatin in the treatment of colorectal cancer
por: Comella, Pasquale, et al.
Publicado: (2009)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
por: Kawai, Sadayuki, et al.
Publicado: (2021)

Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines
por: Nannizzi, Sara, et al.
Publicado: (2009)

Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer
por: Jonker, D., et al.
Publicado: (2006)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
por: Adema, Auke D., et al.
Publicado: (2011)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
por: Sheikh, H Y, et al.
Publicado: (2007)

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2005)

Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
por: Flis, Sylwia, et al.
Publicado: (2009)

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines
por: Yang, Chao, et al.
Publicado: (2016)

Synergistic effects of dendrosomal nanocurcumin and oxaliplatin on oncogenic properties of ovarian cancer cell lines by down-expression of MMPs
por: Seyed Hosseini, Elahe, et al.
Publicado: (2023)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Hepatic encephalopathy coexists with acquired chronic hepatocerebral degeneration
por: Huang, Feng-Zhen, et al.
Publicado: (2015)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2
por: Sun, Wei, et al.
Publicado: (2021)

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
por: Paré, L, et al.
Publicado: (2008)

Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
por: Paré, L, et al.
Publicado: (2009)

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function
por: Van Der Steen, Nele, et al.
Publicado: (2020)

Screening of molecular targets and construction of a ceRNA network for oxaliplatin resistance in colorectal cancer
por: Wei, Wu, et al.
Publicado: (2019)

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2006)

Epithelial Ovarian Carcinoma Types and the Coexistence of Ovarian Tumor Conditions
por: van Niekerk, Catharina. C., et al.
Publicado: (2011)

Coexistence of Ovarian Endometrioma and Ovarian Pregnancy: A Case Report
por: Aoyagi, Yoko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hotljh6hmnvqpb7l8c3499h921